SCHEMBL11973407

SCHEMBL11973407

NC(=O)c1ccc2c(c1)-c1ccc3cccnc3c1NS2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 15/20 0.62
▸ PARP1 P09874 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ TDP1 Q9NUW8 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NFKBIA P25963 4/20 0.40
▸ RELA Q04206 4/20 0.40
▸ LMNA P02545 2/20 0.40
▸ ALOX15 P16050 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ RIPK1 Q13546 1/20 0.40
▸ AR P10275 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11973758 0.89 SLC40A1 (0.61) SLC40A1KDM4EMAPTTDP1MEN1
SCHEMBL11973458 0.85 SLC40A1 (0.66) SLC40A1KDM4EMAPTTDP1MEN1
SCHEMBL11973701 0.85 SLC40A1 (0.64) SLC40A1KDM4EMAPTTDP1MEN1
SCHEMBL11973352 0.85 SLC40A1 (0.47) SLC40A1KDM4EMAPTTDP1MEN1
SCHEMBL11973036 0.81 LMNA (0.43) SLC40A1KDM4EMAPTTDP1MEN1
SCHEMBL11973491 0.81 SLC40A1 (0.49) SLC40A1KDM4EMAPTTDP1MEN1
SCHEMBL11973690 0.79 SLC40A1 (0.50) SLC40A1KDM4EMAPTTDP1MEN1
SCHEMBL18434446 0.79 SLC40A1 (0.57) SLC40A1KDM4EMAPTTDP1MEN1
SCHEMBL18434829 0.79 SLC40A1 (0.57) SLC40A1KDM4EMAPTTDP1MEN1
SCHEMBL11973778 0.78 SLC40A1 (0.51) SLC40A1KDM4EMAPTTDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 — — EP disclosed
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 — — EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885PARP1 4390/4885KDM4E 4215/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885PARP1 4390/4885KDM4E 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback